Table 12.
Phenotypes of presumptive ESBL‐, AmpC‐ or CP‐ producing indicator E. coli subjected to supplementary testing (panel 2). EU MSs and non‐MSs, 2019–2020
| Animal category |
ESBL and/or AmpC n (% R) |
ESBL( a ) n (% R) |
AmpC( b ) n (% R) |
ESBL + AmpC( c ) n (% R) |
CP( d ) n (%R) |
|---|---|---|---|---|---|
| Pigs, 2019 (N = 4,802) | 58 (1.2) | 44 (0.8) | 14 (0.3) | 0 | 0 |
| Calves, 2019 (N = 2,136) | 22 (1.0) | 20 (0.9) | 2 (0.1) | 0 | 0 |
| Broilers, 2020 (N = 4,716) | 54 (1.1) | 45 (1.0) | 16 (0.3) | 7 (0.1) | 0 |
| Turkeys, 2020 (N = 1,875) | 24 (1.3) | 19 (1.0) | 8 (0.4) | 3 (0.2) | 0 |
ESBL: extended‐spectrum β‐lactamase; CP: carbapenemase; N: Total number of isolates reported by MSs and non‐MSs; n: number of isolates with this phenotype; % R: percentage of isolates from the total tested; ESBL; extended‐spectrum β‐lactamase.
All isolates showing clavulanate synergy with cefotaxime, ceftazidime or with both compounds, suggesting the presence of an ESBL (independently of the presence of other mechanisms).
Isolates with microbiological resistance to cefoxitin, suggesting the presence of an AmpC enzyme (independently of the presence of other mechanisms).
Isolates showing synergy with cefotaxime or ceftazidime and with microbiological resistance to cefoxitin, suggesting the presence of ESBL and AmpC enzymes in the same isolate. These isolates are also included in the ESBL and AmpC columns.
Isolates with microbiological meropenem resistance.